About this trial
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator’s choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator’s choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer).
Patient Profile
Triple negative early staged breast cancer
Where’s this trial being run?
Beaumont Hospital, University Hospital Limerick, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ALEXANDRA/IMpassion030 |
|---|---|
| Number: | 17-15 (WO39391 / BIG 16-05) |
| Full Title: | A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer |
| Principal Investigator: | Prof Michaela Higgins (Mater Misericordiae University Hospital) |
|---|---|
| Type: | Collaborative |
| Sponsor: | Hoffmann-La Roche |
| Recruitment Started: |
Global: 2018 Ireland: 2019 |
| Global Recruitment Target: | 2300 |
|---|---|
| Ireland Recruitment Target: | 28 |